Ryan White HIV/AIDS Program — Treatment & Care

The Ryan White HIV/AIDS Program (administered by HRSA) (42 U.S.C. §§ 300ff-11 through 300ff-121) is the largest federal program specifically dedicated to providing HIV/AIDS treatment, care, and support services to people living with HIV who are uninsured or underinsured — serving as the payer of last resort for approximately 568,000 people annually (roughly half of all people diagnosed with HIV in the United States). Named after Ryan White, an Indiana teenager who contracted HIV through a blood transfusion and became a national symbol of the epidemic's human toll, the program was first enacted in 1990 and has been reauthorized four times. Ryan White funds flow through five Parts: Part A (grants to cities hardest hit by HIV), Part B (grants to states, including the AIDS Drug Assistance Program (ADAP) — the nation's largest source of HIV medication for uninsured patients), Part C (grants to community health centers), Part D (grants for women, infants, children, and youth), and Part F (dental, education, and training programs). The program receives approximately $2.4 billion annually and is administered by the Health Resources and Services Administration (HRSA).

Current Law (2026)

Legal Authority

• 42 U.S.C. § 300ff-11 — Part A — Grants to eligible metropolitan areas (EMAs with 2,000+ cumulative AIDS cases receive formula and supplemental grants for outpatient/ambulatory health services, support services, and early intervention)
• 42 U.S.C. § 300ff-21 — Part B — Grants to states and territories (formula grants for HIV care, treatment, and support services; includes ADAP funding for HIV medications; states receive a minimum base grant plus additional funding based on living HIV cases)
• 42 U.S.C. § 300ff-51 — Part C — Early Intervention Services (grants to public and nonprofit entities providing comprehensive primary care and HIV testing in community settings)
• 42 U.S.C. § 300ff-71 — Part D — Women, infants, children, and youth (grants for family-centered care, perinatal HIV prevention, and youth-focused services)

How It Works

Ryan White's defining characteristic is that it is a payer of last resort: if a person living with HIV has Medicaid, Medicare, private insurance, or any other coverage, that coverage pays first. Ryan White covers what's left — copays, deductibles, services not covered by insurance, and full coverage for those with no insurance at all. The ACA's Medicaid expansion reduced the number of uninsured people living with HIV, but Ryan White remains essential for people in non-expansion states, undocumented immigrants ineligible for most federal coverage, and those who need services (case management, transportation, housing assistance) that insurance doesn't cover. The program's most critical component is Part B's AIDS Drug Assistance Program (ADAP), which provides HIV antiretroviral medications to approximately 260,000+ people who would otherwise be unable to afford them. HIV treatment has transformed from a death sentence to a manageable chronic condition — but only with consistent access to antiretroviral therapy (ART), which costs $20,000–$40,000+ per year without insurance. ADAP formularies cover the full range of FDA-approved HIV medications; many state ADAPs also use Ryan White funds to purchase private insurance for clients when that is more cost-effective than directly paying for drugs. Part A provides grants to Eligible Metropolitan Areas (EMAs) — metro areas with 2,000+ cumulative AIDS cases — and Transitional Grant Areas (TGAs) — areas with 1,000–1,999 cases — funding comprehensive care: outpatient medical care, mental health services, substance abuse treatment, case management, oral health, medical nutrition therapy, transportation, and housing assistance.

Ryan White funding is structured around the HIV care continuum: diagnosed → linked to care → retained in care → prescribed ART → viral suppression. A person who achieves viral suppression (undetectable viral load) cannot transmit the virus — so the program's public health and individual health goals are the same. Ryan White-funded programs achieve viral suppression rates of approximately 90% among clients in care, significantly above the national average. Medical treatment alone isn't enough: people living with HIV face barriers to staying in care — poverty, housing instability, mental illness, substance abuse, stigma, transportation challenges, immigration status. Ryan White funds case management (navigating complex health and social service systems), medical transportation, food and nutrition services, and language and cultural services to address these barriers and keep people engaged in treatment. Housing assistance for people living with HIV flows through HUD's separate HOPWA (Housing Opportunities for Persons with AIDS) program.

How It Affects You

If you're living with HIV and don't have adequate coverage: Ryan White is the safety net built specifically for you. The program serves approximately 568,000 people annually — roughly half of everyone diagnosed with HIV in the United States. To access services: start at HRSA's Ryan White HIV/AIDS Program Services Locator (hab.hrsa.gov/get-hiv-care/find-care-near-you) or call 1-800-448-0440 to find funded clinics in your area. ADAP (AIDS Drug Assistance Program, Part B) provides HIV antiretroviral medications to 260,000+ uninsured or underinsured patients — without ADAP, these drugs cost $20,000–$40,000+ per year. Contact your state health department's HIV/AIDS office to apply; income thresholds typically run 300–500% of the federal poverty level, making ADAP available to many people who earn too much for Medicaid but can't afford HIV drugs. As of 2025, ADAP waitlists have returned in some states due to funding cuts combined with higher drug costs from long-acting injectables — if you're placed on a waitlist, ask about short-term drug manufacturer patient assistance programs (Gilead's Advancing Access, ViiV Healthcare's Positive Pathways) to bridge until ADAP coverage begins. Ryan White is the payer of last resort — if you have Medicaid, Medicare, or private insurance, those pay first, and Ryan White covers what they don't (copays, uncovered services, non-medical support).

If you're a healthcare provider or clinic serving HIV patients: Ryan White Part C grants are the primary federal funding stream for community-based HIV primary care outside of hospitals — roughly 1,300 organizations receive Part C grants. Part C-funded organizations typically provide comprehensive primary care, HIV testing, antiretroviral therapy initiation, lab work, adherence counseling, and referrals. If your clinic is not yet a Ryan White Part C grantee and serves a significant HIV population, HRSA announces Part C funding opportunities through Notices of Funding Opportunity at grants.gov. The AIDS Education and Training Centers (AETCs) — Part F — provide free clinical training in HIV management for primary care providers, dentists, nurses, and pharmacists; find your regional AETC at aidsetc.org. Ryan White Part C grantees also have access to the 340B drug pricing program, which allows them to purchase outpatient drugs at substantially discounted prices (typically 25-50% below wholesale) — a critical tool for making HIV care financially sustainable. See 340B Drug Pricing for how to ensure your organization is maximizing 340B benefits.

If you're a state health official or ADAP administrator: Part B grants are formula-based (on living HIV cases in your state plus a base grant) and are the backbone of state HIV infrastructure. The most operationally critical Part B use is ADAP — your ADAP's formulary, income eligibility threshold, enrollment process, and waiting list status are the primary determinants of medication access for uninsured people with HIV in your state. The 2025 OBBBA cuts reduced Ryan White appropriations approximately 8-12%, and the simultaneous shift toward long-acting injectable ART (Cabenuva at $42,000/year vs. Biktarvy at $15,000/year) is creating formula pressure. ADAP waitlists returning are a serious program signal. If your state is considering income eligibility cuts to manage budget pressure, model the downstream effect: people who lose ADAP access often go to emergency care when their viral load rebounds, which costs far more per patient. Some states use Part B funds to purchase marketplace insurance for ADAP clients as an insurance purchasing program — this can extend reach if managed carefully.

If you follow healthcare or public health policy: Ryan White is the quiet infrastructure underneath the HIV epidemic's public health progress. The U.S. has achieved viral suppression rates of approximately 90% among Ryan White clients — compared to roughly 65% for all people living with HIV nationally — demonstrating what a well-funded care-and-support system can do. The Ending the HIV Epidemic (EHE) initiative targets the 50 counties, Washington D.C., San Juan PR, and 7 states where 50% of new infections occur, aiming to reduce new infections by 90% by 2030. Ryan White programs are the primary delivery mechanism for EHE. The 2025 DOGE-driven cuts to HRSA and CDC staff are a compounding risk: Ryan White programs depend on HRSA technical assistance and CDC surveillance data to function — reduced surveillance means slower detection of outbreaks and less evidence for EHE targeting. If you're watching for program deterioration signals, the ADAP waitlist status (updated monthly at nastad.org/adap-watch) and the number of Ryan White clients achieving viral suppression are the key quality indicators.

State Variations

Ryan White operates through state and local grants:

• State ADAPs vary significantly in formulary breadth, eligibility income limits (typically 300–500% FPL), and services offered
• Some states use ADAP funds to purchase marketplace insurance for clients; others provide medications directly
• Medicaid expansion states have fewer uninsured people living with HIV, reducing but not eliminating Ryan White demand
• State public health departments administer Part B grants and set state-level priorities
• Local planning councils (Part A) determine how metropolitan area funds are allocated among service categories

Implementing Regulations

• 42 CFR Part 51b — CDC project grants for preventive health services (HIV/AIDS prevention programs)
• 45 CFR Part 96 — Block grants (substance abuse and HIV prevention services)
• HRSA Ryan White Program Notices — HRSA administers Parts A-F through program guidance, Notices of Funding Opportunity, and policy clarification notices rather than formal CFR regulations

Pending Legislation

Ryan White reauthorization provisions appear in broader public health legislation. See Public Health Service Act and HIV/AIDS Policy.

Recent Developments

The Ending the HIV Epidemic (EHE) initiative — launched in 2019 — targets the 50 counties, Washington D.C., San Juan, and 7 states with the highest HIV rates, aiming to reduce new infections by 90% by 2030. Ryan White programs are a critical delivery mechanism for EHE, providing the care infrastructure in targeted jurisdictions. The adoption of long-acting injectable antiretroviral therapy (cabotegravir/rilpivirine, administered monthly or bimonthly) is changing ADAP formulary and delivery dynamics. PrEP (pre-exposure prophylaxis) for HIV prevention has become widely available, further reducing new infections, though Ryan White funds are primarily treatment-focused. The program continues to serve as the model for how a comprehensive, coordinated care system can achieve public health goals through a payer-of-last-resort structure.

• OBBBA Ryan White funding cuts (2025): The One Big Beautiful Bill Act reduced discretionary appropriations for HRSA programs including Ryan White. Ryan White's Parts A-F are funded through annual appropriations; the OBBBA cuts reduced total Ryan White funding by approximately 8-12% from peak levels. ADAP waitlists — eliminated by expanded funding in 2012 — began returning in some states as per-capita drug costs increased (driven by long-acting injectables) while appropriations declined. The return of ADAP waitlists is a sentinel indicator of Ryan White program stress; people on ADAP waitlists are without antiretroviral therapy, which is both a health and public health crisis.
• Long-acting injectable ART — cost and formulary challenges: Long-acting injectable antiretroviral therapy (cabotegravir/rilpivirine, branded as Cabenuva; lenacapavir, branded as Sunlenca for monthly or twice-yearly injection) is dramatically more convenient than daily oral therapy and improves adherence. However, injectable ART costs $25,000-$42,000 per year versus $10,000-$15,000 for oral regimens. ADAP formularies must cover injectable ART to meet modern standard of care; the higher costs reduce the number of people ADAP can serve with flat or declining appropriations. HRSA is developing national formulary guidance on when ADAP must cover injectable versus oral therapy.
• DOGE and EHE infrastructure: DOGE-driven cuts to CDC and HRSA program staff affected the Ending the HIV Epidemic (EHE) initiative's data surveillance, programmatic support, and technical assistance infrastructure. CDC's Division of HIV Prevention — which provides the surveillance data that identifies EHE target counties and tracks progress toward the 90% reduction goal — faced staffing reductions. Without surveillance data, the EHE's evidence-based targeting strategy cannot function; lost progress in reducing new infections in target jurisdictions was documented in CDC's 2025 HIV Surveillance Report.
• PrEP access and Braidwood litigation: The Supreme Court's Braidwood Management v. Becerra decision (2024, remanded from 5th Circuit) threatened to eliminate the ACA's mandate that private insurers cover PrEP for HIV prevention without cost-sharing. The 5th Circuit held that the ACA's requirement to cover preventive services recommended by the U.S. Preventive Services Task Force after 2010 violates the non-delegation doctrine. If the Supreme Court affirms, PrEP cost-sharing could return for private insurance enrollees — the Braidwood plaintiffs are specifically objecting to PrEP coverage on religious grounds. Ryan White's ADAP covers PrEP for eligible clients regardless of the Braidwood outcome, but millions of commercially insured PrEP users depend on the ACA's no-cost-sharing mandate.